These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 10562769

  • 1. New fluoroquinolone antibiotics.
    Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769
    [Abstract] [Full Text] [Related]

  • 2. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
    Goldstein EJ.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
    [Abstract] [Full Text] [Related]

  • 3. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC.
    Curr Clin Top Infect Dis; 2000 Dec; 20():63-91. PubMed ID: 10943519
    [No Abstract] [Full Text] [Related]

  • 4. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ.
    Drugs; 2002 Dec; 62(1):13-59. PubMed ID: 11790155
    [Abstract] [Full Text] [Related]

  • 5. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
    Scheen AJ.
    Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
    [Abstract] [Full Text] [Related]

  • 6. Levofloxacin.
    Norrby SR.
    Expert Opin Pharmacother; 1999 Nov; 1(1):109-19. PubMed ID: 11249554
    [Abstract] [Full Text] [Related]

  • 7. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
    Ernst ME, Ernst EJ, Klepser ME.
    Am J Health Syst Pharm; 1997 Nov 15; 54(22):2569-84. PubMed ID: 9397218
    [Abstract] [Full Text] [Related]

  • 8. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ, Jung R, Garvin CG.
    Drug Saf; 2001 Nov 15; 24(3):199-222. PubMed ID: 11347723
    [Abstract] [Full Text] [Related]

  • 9. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ, Meyer JM, Chuck SK, Jung R, Messick CR, Pendland SL.
    Ann Pharmacother; 1998 Mar 15; 32(3):320-36. PubMed ID: 9533064
    [Abstract] [Full Text] [Related]

  • 10. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD, Lamb HM.
    Drugs; 1998 Sep 15; 56(3):487-515. PubMed ID: 9777318
    [Abstract] [Full Text] [Related]

  • 11. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV, Vasil'ev AN, Smirnova LB.
    Antibiot Khimioter; 2001 Sep 15; 46(7):38-46. PubMed ID: 11697244
    [No Abstract] [Full Text] [Related]

  • 12. Activity of levofloxacin, ofloxacin, D-ofloxacin and ciprofloxacin against systemic and respiratory tract infections in laboratory animals.
    Klesel N, Geweniger KH, Koletzki P, Isert D, Limbert M, Markus A, Riess G, Schramm H, Seibert G, Iyer P.
    Drugs; 1995 Sep 15; 49 Suppl 2():211-4. PubMed ID: 8549307
    [No Abstract] [Full Text] [Related]

  • 13. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R, Andrews JM.
    J Antimicrob Chemother; 1997 Dec 15; 40 Suppl A():27-30. PubMed ID: 9484870
    [Abstract] [Full Text] [Related]

  • 14. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R, Andrews JM.
    J Chemother; 1998 Aug 15; 10(4):276-9. PubMed ID: 9720464
    [Abstract] [Full Text] [Related]

  • 15. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
    Evans ME.
    Eur J Clin Microbiol Infect Dis; 2001 Dec 15; 20(12):883-5. PubMed ID: 11837640
    [Abstract] [Full Text] [Related]

  • 16. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep 15; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 17. Antibacterial activity of grepafloxacin.
    Wiedemann B, Heisig P.
    J Antimicrob Chemother; 1997 Dec 15; 40 Suppl A():19-25. PubMed ID: 9484869
    [Abstract] [Full Text] [Related]

  • 18. Levofloxacin, a second-generation fluoroquinolone.
    North DS, Fish DN, Redington JJ.
    Pharmacotherapy; 1998 Dec 15; 18(5):915-35. PubMed ID: 9758306
    [Abstract] [Full Text] [Related]

  • 19. Grepafloxacin.
    Wagstaff AJ, Balfour JA.
    Drugs; 1997 May 15; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [Abstract] [Full Text] [Related]

  • 20. Safety of the new fluoroquinolones compared with ciprofloxacin.
    Ball P.
    J Chemother; 2000 Jan 15; 12 Suppl 1():8-11. PubMed ID: 11414383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.